ArticleMolecular biology reports2026
Modulatory role of blackberry fruit standardized extract on brain redox status and insulin signaling in type 2 diabetic rats.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored the effect of blackberry fruit extract (BFE) and metformin (Met) on biochemical markers, redox parameters, and the downstream insulin signaling pathway in a high-fat diet (HFD) + streptozotocin (STZ) induced Type 2 Diabetic Rat model.
methodsThe identification and quantification of cyanidin-3-glucoside by HPLC in the BFE revealed a concentration of 28.33 ± 0.05 mg/g of dry extract. For in vivo study, Type 2 Diabetes Mellitus (T2DM) was induced in rats by feeding a HFD for 3 weeks, followed by a single intraperitoneal dose of STZ on day 21. Animals were divided into 4 groups: I – Control, II – T2DM, III – T2DM plus Met (250 mg/kg) and IV – T2DM plus BFE (200 mg/kg). After STZ administration, the animals underwent a glucose tolerance test. Biochemical and molecular analyses were performed in serum and brain tissues.
resultsBFE and Met improved diabetic parameters, mitigating hyperglycemia, dyslipidemia, and inflammation by lowering serum glucose, total cholesterol, triglycerides, very low-density lipoprotein, interleukin-6, adenosine deaminase activity, and reactive species levels, while restoring high-density lipoprotein and paraoxonase-1 activity in blood. Both treatments reduced oxidative stress in the cerebral cortex by lowering reactive species, nitrite, and thiobarbituric acid reactive substances levels and increasing sulfhydryl groups, superoxide dismutase and catalase activity. Also, BFE upregulated phosphatidylinositol 3-kinase, insulin receptor substrate-1, forkhead box O-3a in the cerebral cortex.
conclusionThese findings highlight the potential of BFE as a promising natural therapeutic agent for T2DM management, demonstrating efficacy comparable to Met in addressing metabolic and oxidative impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.